Key result
Treatment with edoxaban 60 mg once daily for 3 months resulted in complete resolution of thrombosis and symptoms in a patient with superior vena cava syndrome after pacemaker implantation.
Why the study?
Superior vena cava syndrome is a rare but serious complication after pacemaker lead implantation, with benign iatrogenic causes becoming increasingly common.
Population
A 75-year-old woman who developed SVC syndrome after transvenous pacemaker implantation
Design
Case report
Follow-up
3 months
Authors
Loading...
May support edoxaban in pacemaker-related SVC syndrome; hypothesis-generating and requires prospective trials before adoption.
Case Report (n=1)
No
Direct oral anticoagulation with edoxaban may be an effective and non-invasive treatment option for superior vena cava syndrome complicating pacemaker implantation.
Mumoli et al. (2021) conducted a case report in Superior Vena Cava (SVC) syndrome (n=1). Edoxaban was evaluated on Resolution of thrombosis. Treatment with edoxaban 60 mg once daily for 3 months resulted in complete resolution of thrombosis and symptoms in a patient with superior vena cava syndrome after pacemaker implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: